US Edition
AstraZeneca Strengthens Its Presence in China with a Strategic Collaboration that Could Reach $5.3 Billion
Summary by Forbes España
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
AstraZeneca has started a strategic research collaboration with the Chinese pharmaceutical company CSPC Pharmaceuticals Group Limited, based in the city of Shijiazhuang, focused on the discovery and development of innovative oral therapies for chronic diseases and that could reach 5.3 billion dollars. This agreement consolidates the expansion of the British company in [...] The entry AstraZeneca strengthens its presence in China with a strategic…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
